Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medifast (MED) EPS (Weighted Average and Diluted) (2016 - 2025)

Medifast (MED) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with -$1.64 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 2442.86% year-over-year to -$1.64, compared with a TTM value of -$1.7 through Dec 2025, down 994.74%, and an annual FY2025 reading of -$1.7, down 994.74% over the prior year.
  • EPS (Weighted Average and Diluted) was -$1.64 for Q4 2025 at Medifast, down from -$0.21 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.96 in Q2 2021 and bottomed at -$1.64 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.71, with a median of $2.28 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 129.33% in 2025, while the deepest fall reached 2442.86% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $2.91 in 2021, then decreased by 15.81% to $2.45 in 2022, then crashed by 77.55% to $0.55 in 2023, then plummeted by 87.27% to $0.07 in 2024, then crashed by 2442.86% to -$1.64 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for MED at -$1.64 in Q4 2025, -$0.21 in Q3 2025, and $0.22 in Q2 2025.